REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for alleged violations of securities laws, specifically related to misleading statements about the company's clinical trial results [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Replimune's securities between November 22, 2024, and July 21, 2025 [2]. - The Schall Law Firm is representing the investors and encourages those who suffered losses to participate in the lawsuit [5]. Group 2: Allegations Against the Company - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE trial for RP1 (vusolimogene oderparepvec) [4]. - It is claimed that the company overstated the prospects of the trial and was aware of material issues that could lead to the FDA deeming the trial inadequate [4]. - As a result of these misleading statements, investors experienced financial damages when the truth about the company's situation was revealed [4].